The Federal Trade Commission is challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic
Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Health Medication Intellectual Property Washington News General News Article 109794072
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Federal Trade Commission rules most noncompetes to be unlawful soonAndrew Christiansen is KGUN 9's Catalina Foothills reporter. Send your story ideas to Andrew at andrew.christiansenkgun9.com.
Lire la suite »
Federal Trade Commission Bans Noncompete Agreements, Urges More Protections for Healthcare WorkersThe FTC's decision to ban noncompete agreements could make it easier for doctors and other healthcare workers to switch jobs. But business groups say they will sue to block it.
Lire la suite »
Federal trade commission sues to block $8.5 billion merger of Coach and Michael KorsThe agency said that the deal would eliminate direct head-to-head competition between the fashion companies’ brands like Coach and Michael Kors in the…
Lire la suite »
Federal Trade Commission sues to block Tapestry's $8.5B acquisition of CapriThe Federal Trade Commission sued to block Tapestry, Inc.’s $8.5 billion acquisition of Capri Holdings Ltd.
Lire la suite »
Federal Trade Commission sues to block Tapestry's $8.5B acquisition of CapriThe Federal Trade Commission sued to block Tapestry, Inc.’s $8.5 billion acquisition of Capri Holdings Ltd.
Lire la suite »
Federal Trade Commission sues to block Tapestry's $8.5B acquisition of CapriThe Federal Trade Commission sued to block Tapestry, Inc.’s $8.5 billion acquisition of Capri Holdings Ltd., saying that the deal would eliminate direct head-to-head competition between the fashion companies’ brands like Coach and Michael Kors in the so-called affordable luxury handbag arena.
Lire la suite »